Literature DB >> 11504505

Topoisomerase I inhibitors: selectivity and cellular resistance.

Yves Pommier1, Philippe Pourquier, Yoshimasa Urasaki, Jiaxi Wu, Gary S. Laco.   

Abstract

Topoisomerase I (top1) inhibitors (camptothecins and other structurally diverse compounds) are effective and promising anticancer agents. Determinants of selectivity toward cancer cells and resistance are multifactorial. These factors can be separated in three groups. The first is related to alterations in drug distribution and metabolism. The second group includes both quantitative and qualitative (mutations) differences in top I. The third group includes resistance and sensitivity factors downstream from the cleavage complexes. They include DNA repair, cell cycle checkpoints and apoptosis, and are probably key to the relative selectivity of camptothecins toward cancer cells and to clinical resistance. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11504505     DOI: 10.1054/drup.1999.0102

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  53 in total

1.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  Protein concerted motions in the DNA-human topoisomerase I complex.

Authors:  Giovanni Chillemi; Paola Fiorani; Piero Benedetti; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

Review 3.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

4.  Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.

Authors:  G Chillemi; M Redinbo; A Bruselles; A Desideri
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

5.  Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Authors:  Jhanelle Gray; Christopher L Cubitt; Shumin Zhang; Alberto Chiappori
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

6.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

7.  New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.

Authors:  David F Fujimoto; Clemencia Pinilla; Anca M Segall
Journal:  J Mol Biol       Date:  2006-08-24       Impact factor: 5.469

Review 8.  Targeting Topoisomerase I in the Era of Precision Medicine.

Authors:  Anish Thomas; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

9.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

Review 10.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.